Other CURES for Cancer

### OTHER CURES for CANCER : (page created February 2007 – last updated June 2007)

## ORMUS seems to be VERY EFFICIENT against many diseases, cancer cured in weeks, see page dedicated ormus_index.html

## Heat may be key to cancer therapy, BBC NEWS 25 July 2006 http://news.bbc.co.uk/2/hi/health/5214030.stm

Researchers believe they have found out why so many men with testicular cancer survive against the odds. Testicular cancer, such as that famously conquered by Tour de France winner Lance Armstrong, is often treatable even when it has spread.

Experts at John Hopkins University say the cells are super-sensitive to body heat making them more vulnerable. And heat therapy may be used to combat other cancers they write in the Journal of the American Medical Association.

The testes are a few degrees cooler than the rest of the body as sperm are sensitive to heat and tend to die when they are placed at the normal body temperature of 37C.

Professor Robert Getzenberg and colleagues at John Hopkins Medical School say several pieces of evidence suggest that testicular cancer cells may also have this sensitivity to heat, making them more amenable to treatment, a phenomenon they term the ‘Lance Armstrong effect’.

So, when the cells spread to other areas of the body, they may be weakened by higher temperatures, becoming more susceptible to chemotherapy or radiotherapy than other types of cancer. Studies in men who have a condition in which the testes do not descend and remain in the body show that the nuclear matrix, the protein scaffolding in the control centre of the cell, becomes ‘wrecked’ and is heat sensitive.

Professor Getzenberg and his team are now experimenting with different methods of weakening the nuclear matrix in cancer cells by heat. “We tried to put our heads together about what we know about the differences between testicular and other cancers. There is an amazing difference in treatment success and we wanted to come up with a simple idea that has a biological basis.”

Professor Getzenberg said heat, or hyperthermia, is a very old form of cancer therapy but in order to make it a successful it needs to be targeted specifically at cancer cells. “Some groups are doing localised heating of tumours but the real advance would be to move this into people with systemic disease. These are not big golf ball size tumours they’re small tumours that you can’t really see.” “We need to think how we can target these cancer cells anywhere in the body.”

Nanoparticles : Professor Getzenberg is using nanotechnology to target iron particles directly to cancer cells. These ‘nanoparticles’ can be developed to be attracted to specific markers present on the surface of cancer cells. Once attached to the cancer cells they can be heated using an external magnetic field, weakening the cells and hopefully making them more susceptible to chemotherapy or radiation.

The team are currently assessing this technique for treating prostate cancer in animal models. “These nanoparticles exist now and can be used in the body. The advantages are you don’t have to put them in every cell as long as you are getting a warming environment,” he said. “We are also working on study on bladder cancer looking at putting a warm solution in the bladder, using a more localised approach.”

Ed Yong, cancer information officer at Cancer Research UK, said: “If cancer cells can be shown to be susceptible to higher temperatures, heat therapy may well become an option for treating cancer patients. “To be effective, the heat must be targeted to cancer cells while leaving healthy cells unharmed. Nanoparticles can provide a way of doing this. “Nanotechnology is a very exciting new field of science and it is set to play an increasing role in detecting and treating cancers.”

## Omega-3 fatty acids during pregnancy and while nursing found to be beneficial. http://www.nutritionhorizon.com/newsmaker_article.asp?idNewsMaker=8014&fSite=AO545&next=0

Prenatal and lactational diet could shield female offspring from breast cancer in later life,

21/04/05 Mothers who eat foods rich in omega-3 fatty acids during pregnancy and while nursing, and who continue to feed their babies such a diet after weaning, may reduce their daughters’ risk of developing breast cancer later in life dramatically, according to research presented at the 96th Annual Meeting of the American Association for Cancer Research.

Either maternal or post-weaning dietary consumption of omega-3 fatty acids through food or supplements at any point in life from conception to at least puberty – also could reduce the incidence rate for breast cancer in female offspring significantly.

Conversely, mothers’ consumption of omega-6 fats commonly found in Western diets could increase their daughters’ risk of breast cancer.

Omega-3 fatty acids occur most commonly in fish – especially cold-water fish such as tuna, salmon and mackerel – as well as in canola and flaxseed oils, soybeans and nuts.

Founded in 1907, the American Association for Cancer Research is a professional society of more than 24,000 laboratory, translational, and clinical scientists engaged in all areas of cancer research in the United States and in more than 60 other countries. AACR’s mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy.

Its principal activities include the publication of five major peer-reviewed scientific journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention.

AACR’s Annual Meetings attract more than 15,000 participants who share new and significant discoveries in the cancer field. Specialty meetings, held throughout the year, focus on the latest developments in all areas of cancer research.


## Glivec help against Leukaemia (CML) http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2006/06/06/ncanc06.xml

One pill a day keeps cancer at bay. By Celia Hall, Medical Editor (Filed: 06/06/2006)

A drug prescribed for one of the commonest forms of leukaemia has reduced the deadly cancer to a chronic illness that can be managed with a single pill a day, specialists said yesterday.

New data issued in London showed that about 90 per cent of patients with chronic myeloid leukaemia (CML) who take the drug Glivec are alive and well after five years.

Before the drug was developed, the blood cancer would become advanced within four to six years, giving little hope of survival.

Specialists described the results as “breathtaking”. They said that, unlike some cancer drugs which had shown early promise that then faded, Glivec patients had an “impressively durable resp-onse to the drug”.

CML is one of the four most common types of leukaemia. It is a blood cancer in which the white blood cells do not mature and are over-produced.

The condition can lead to tumours forming on the bone marrow or lymph nodes and can also increase the risk of strokes and life-threatening infections.

Patients take the drug for life. In some it is weeks before real benefits can be measured but other patients report feeling better within a few days. While the drug does not cure the leukaemia, it keeps it under control.

Before Glivec, patients with CML had a life expectancy of four to six years. In the long-term trial only 4.6 per cent of patients died. The drug costs the health service from £14,000 a year per patient, depending on the strength of the dose, and is recommended for those for whom a bone marrow transplant is not an option.

Pennie Douglas, of CML Support, said her organisation was worried that not all patients had swift access to the drug or that they remained on it. “We are concerned about people who are not treated at the specialist centres. There are misunderstandings at some hospital departments. “We have heard that some patients whose test results are good are taken off it. It is a funding issues for many primary care trusts.”

About 3,000 people in the country have CML and about 600 a year are newly diagnosed. It usually strikes in middle age.

Glivec is also having good results with a rare cancer of the digestive tract known as gist and is being tried with other cancers, including some that attack the prostate, lungs and brain. Glivec is designed to stop the cancer cells from multiplying. It works by blocking or inhibiting signals that instruct the cancers cells to divide and grow. Sufferers normally take one tablet a day for as long as it is shown that they continue to benefit from it.

Users of the drug have reported some mild side-effects, including nausea and sometimes diarrhoea. It can also cause leg aches and cramp, rashes and swelling of the face, especially around the eyes. Such side-effects are usually treatable.

Charles Craddock, professor of haematology at Birmingham University and the director of the stem cell transplant unit at the city’s Queen Elizabeth Hospital, said that results from earlier drug treatments for CML had been “pretty gloomy”. “I am delighted that the remarkable results we initially saw in CML patients treated with Glivec five years ago have continued to improve. “The significant success of Glivec in treating CML is an exciting model for the development of new treatments for other cancers.”

Dave Cook, a spokesman, said: “The data that we have seen confirm what I have experienced for myself. When six separate gists were removed, I was devastated but after four years on Glivec my scans show no signs of any abnormality. Glivec is a life-saver.”

Sandy Craine, 58, from Liverpool, was one of the first people in Britain to take Glivec and formed a support group. She said: “When it became available five years ago I never believed that I would be standing here today. “I was told that without invasive chemotherapy following a stem cell transplant I had approximately 12 months to live. “It has helped save to my life and I am so grateful that I can pass on this message of hope to others diagnosed with this once devastating disease.”

Publishers wishing to reproduce photographs on this page should phone 44 (0) 207 538 7505 or e-mail syndication@telegraph.co.uk

## Cancer Curing Blood , by Eva Gladek and Joyce Gramza, 06.06.06, http://www.sciencentral.com/articles/view.php3?type=article&article_id=218392802

It’s a discovery in animals that would change everything if it turns out to be true in people. An injection of blood cells from cancer-resistant mice cures cancer in ordinary mice. As this ScienCentral News video explains, there may be a way to identify cancer-resistant people.

The End of Cancer?

A universal treatment that would work against any type of cancer has always seemed like a far-fetched fantasy. But now researchers at Wake Forest University have made a discovery in mice that might one day lead to a “magic bullet” against human cancers if it proves to be true in people. Several years ago, the researchers identified a rare strain of mouse immune to high, usually lethal doses of cancer cells. Now they have shown that not only are these mice cancer-resistant, but their immune cells are also capable of curing normal, non-resistant mice of any type of advanced cancer.

As reported in Proceedings of the National Academy of Sciences, lead researcher Zheng Cui and his team injected white blood cells from the cancer-resistant mice into normal mice with aggressive cancers that should have killed them in two to three weeks. Instead, their cancer disappeared.

“Cancer cells had already developed a large tumor in the mice, and at a different place [than] where we put the immune cells in,” says Cui, “That would require the immune cells to find them at a different part of the body and then track them down to the site and destroy the cancer cells.”

The researchers have bred a large colony of the cancer-resistant mice, all from one mouse they discovered in 1999. In previous studies the team showed that the resistant mice can survive very large doses – up to 3 billion cells – of any kind of cancer. This resistance is passed on genetically in a “perfect Mendelian single dominant gene pattern,” says Cui, since the trait is transmitted to roughly half of each resistant-mouse’s offspring. On this basis the scientists believe the resistance mutation must be in a single gene.

But after seven years of searching for the gene, the researchers have yet to identify it. “There isn’t any reason to think it’s not a single gene, it just turns out that analysis of that genetics is somewhat more complex than one would have predicted,” says pathologist Mark Willingham, a co-author of the paper.

Their past work also clearly showed that the gene worked by somehow activating the immune systems of these resistant mice to selectively target cancer cells. Their most recent research confirms that the immune cells that do the cancer killing belong to the innate immune system. They recognize cancer cells as foreign and attack them without having any prior exposure to them.

“I think the surprise from this mouse model is that it involves a part of the immune system that would not have been predicted,” says Willingham.When the researchers isolated different types of innate immune system cells from the resistant mice and tested them against cancer cells, they got another surprise: the cancer resistance was not confined to just one type of immune cell. “All [the types] can be independently killing [cancer] cells without the other subtypes present,” says Cui.

A funder of the study, the Cancer Research Institute, which backs immunological approaches to cancer diagnosis and treatment, is funding collaborations with Bruce Beutler, M.D., an immunogeneticist at the Scripps Research Institute, to help search for the gene, and with Robert D. Schreiber, Ph.D., a molecular immunopathologist at the Washington University School of Medicine in St. Louis, who will test the cancer-resistant cells on his mouse models of naturally arising cancers.

Unconventional ideas

The researchers also developed a blood test that can identify the cancer-resistant mice without having to challenge them with cancer. They hope a similar test might help find and study cancer-resistance in people.

“If this were to be the same in humans we could simply identify cancer-resistant humans and to do the blood transfusion or white blood cell transfusion without even knowing the mechanism to find out whether it will work or not,” says Cui, “So that’s obviously on everybody’s mind.”

The researchers say they’ve heard from many cancer patients and their loved ones excited about the tantalizing possibility that blood and bone marrow banks might also contain cancer curing cells. Cui points out that it could take years to find the gene, and many more to develop and test drugs that target it. In the meantime, his team has begun to test blood samples from healthy people, and have found a wide range of cancer-killing activity in humans. “We are forced and compelled to do this kind of experiment … I think it’s our responsibility as cancer researchers,” Cui says. But he also acknowledges that he is having a hard time getting funding for this approach. “It’s obviously a very unconventional way of doing science nowadays,” he says. “It’s not mechanism-based … it’s simple mimicry of what happened in the mice.”

Indeed, cell biologist Jill O’Donnell-Tormey, executive director of the Cancer Research Institute, says it’s important to first understand the genetic and biological basis of these cancer killing blood cells.”There is some indication that a similar mechanism that we’re seeing in these remarkable mice are also present in humans but we think we have a ways to go in terms of doing a good deal of research before we can actually answer that question,” she says.

Cui says he would like to pursue both the conventional and unconventional approaches. “We think there might actually be a possibility we could do it without knowing the mechanism,” he says, “but of course by knowing the mechanism you could devise many other options, so if one thing doesn’t work then you can also find different ways using the same concept. So we think both directions are important.”

He notes, however, that if the cell-donation approach were to work in people, it would not need to go through a long FDA approval process. “All the delivery mechanisms are already in place and all the ethical regulations for that direction are already in place. So if we can identify cancer-resistant humans then they could start treating them tomorrow if someone wants to pay for it.”

This most recent finding by Cui and his team was published in the May 16, 2006 Proceedings of the National Academy of Sciences (PNAS). The research is funded by the Cancer Research Institute (CRI), National Cancer Institute (NCI), and the Charlotte Geyer Foundation.

Scroll to Top